retatrutide phase 2 trial obesity nejm 2023 triple agonist 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ retatrutide phase 2 results obesity

Many patients notice reduced appetite early in treatment, with continued progress over time when combined with healthy nutrition, regular physical activity, and lifestyle changes

For instance, patients with a history of pancreatitis should exercise caution, and those with personal or family histories of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should avoid GLP-1 receptor agonists, as rodent studies have indicated a potential risk of thyroid tumors

Why you'll love it: Natural caffeine equivalent to two espresso shots

Learn about the peptide therapies currently available at Perfect B in Doral, FL Stacking AOD 9604: Common Research Protocol Combinations AOD 9604 is frequently evaluated in combination with other peptides, particularly in protocols designed for body recomposition rather than pure weight loss